Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA416315 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR6255900_1.fastq.gz | Fastqsanger.gz | |||
| SRR6255900_2.fastq.gz | Fastqsanger.gz | |||
| SRR6255910_1.fastq.gz | Fastqsanger.gz | |||
| SRR6255910_2.fastq.gz | Fastqsanger.gz | |||
| SRR6255920_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 838 |
Similar Datasets
Project description:Profiling of prostate tissues in prostate cancer progression
| PRJNA101627 | ENA
Project description:Proteomic sequencing was performed on 5 prostate cancer patient tissues and 5 benign prostatic hyperplasia patient tissues collected from Beijing Tongren Hospital Affiliated to Capital Medical University. Differential genes related to the prognosis of prostate cancer were identified, and enrichment analysis was conducted on prostate cancer patients based on these genes to clarify the biological functions in prostate cancer cells that significantly affect cancer cell progression. Lactylation modification proteomic sequencing revealed the sites in prostate cancer that promote prostate cancer progression due to lactylation modification, providing potential therapeutic methods for the treatment of prostate cancer.
2026-01-23 | PXD066054 | Pride
Project description:Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment options for advanced stages. This proteogenomics study aims to integrate multi-omics approaches, including proteomics, genomics, and transcriptomics, to elucidate the molecular mechanisms underlying lung cancer progression and treatment resistance. By leveraging cutting-edge technologies, this study seeks to identify novel biomarkers and therapeutic targets, enabling personalized medicine strategies to improve patient outcomes. The integration of proteogenomic data will provide a comprehensive understanding of tumor biology, revealing critical pathways and interactions that drive tumorigenesis and immune evasion.
2024-12-02 | GSE283245 | GEO
Project description:Although many treatment options have been adopted in patients with metastatic hormone sensitive prostate cancer (mHSPC), such as early docetaxel and AR-targeting therapy, there are currently no optimal biomarkers to guide treatment in these patients. To understand the transcriptomic features in mHSPC patients treated by either docetaxel or abiraterone acetate by performing whole transcriptome sequencing (WTS) and single cell RNA sequencing (scRNA-seq).
2024-07-31 | GSE221603 | GEO
Project description:Although many treatment options have been adopted in patients with metastatic hormone sensitive prostate cancer (mHSPC), such as early docetaxel and AR-targeting therapy, there are currently no optimal biomarkers to guide treatment in these patients. To understand the transcriptomic features in mHSPC patients treated by either docetaxel or abiraterone acetate by performing whole transcriptome sequencing (WTS) and single cell RNA sequencing (scRNA-seq).
2024-07-31 | GSE221601 | GEO
Project description:<p>The spread of cancer to bone is invariably fatal, with complex cross-talk between tumor cells and the bone microenvironment responsible for driving disease progression. By combining in silico analysis of patient datasets with metabolomic profiling of prostate cancer cells cultured with bone cells, we demonstrate the changing energy requirements of prostate cancer cells in the bone microenvironment, identifying the pentose phosphate pathway (PPP) as elevated in prostate cancer bone metastasis, with increased expression of the PPP rate-limiting enzyme glucose-6-phosphate dehydrogenase (G6PD) associated with a reduction in progression-free survival. Genetic and pharmacologic manipulation demonstrates that G6PD inhibition reduces prostate cancer growth and migration, associated with changes in cellular redox state and increased chemosensitivity. Genetic blockade of G6PD in vivo results in reduction of tumor growth within bone. In summary, we demonstrate the metabolic plasticity of prostate cancer cells in the bone microenvironment, identifying the PPP and G6PD as metabolic targets for the treatment of prostate cancer bone metastasis.</p>
2024-08-19 | MTBLS3973 | MetaboLights
Project description:Integrative Molecular Concepts Modeling of Prostate Cancer Progression
| PRJNA97661 | ENA
Project description:Protein 4.1B suppresses prostate cancer progression and metastasis
| PRJNA100091 | ENA
Project description:Metastatic, castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer with a high mortality rate due to a current lack of treatment options. While much is already known about how mutations in protein-coding sequences across the genome affect prostate cancer, somatic mutations occurring in the 3’ untranslated regions (3’UTRs) of genes are largely unstudied. The 3’UTR is a genomic region that controls post-transcriptional gene expression through its recruitment of trans-acting factors such as RNA-binding proteins (RBPs) and microRNAs (miRNAs), which themselves are known to be oncogenes and tumor suppressors in many cases. To better understand the role of 3’UTR mutations across prostate cancer, we have created a database of 3’UTR somatic mutations in 185 patients with mCRPC, discovering 14,497 single-nucleotide mutations throughout the 3’UTRome. In order to functionally assay these variants, we have developed a novel pair of massively parallel reporter assays (MPRA) able to determine the effect of thousands of patient somatic mutations on post-transcriptional gene expression. In this two-pronged approach, we are able to measure whether each of 6,892 mutations found in recurrently mutated 3’UTRs affect mRNA stability, steady-state transcript level, and translation efficiency. This deep functional assessment of thousands of 3’UTR mutations allows us to uncover patterns in mutation functionality, including their association with RNA motifs and sequence conservation. Investigation into how the resultant gene expression changes from 3’UTR mutations affect prostate cancer pathogenesis, such as cancer growth or response to treatment, is also underway. This work represents an unprecedented view of the extent to which disease-relevant 3’UTR mutations affect mRNA stability, translation efficiency, and cancer phenotypes, expanding the boundaries of functional cancer genomics and potentially uncovering novel therapeutic targets in previously unexplored regulatory regions.
2023-06-30 | GSE200303 | GEO
Project description:Metastatic, castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer with a high mortality rate due to a current lack of treatment options. While much is already known about how mutations in protein-coding sequences across the genome affect prostate cancer, somatic mutations occurring in the 3’ untranslated regions (3’UTRs) of genes are largely unstudied. The 3’UTR is a genomic region that controls post-transcriptional gene expression through its recruitment of trans-acting factors such as RNA-binding proteins (RBPs) and microRNAs (miRNAs), which themselves are known to be oncogenes and tumor suppressors in many cases. To better understand the role of 3’UTR mutations across prostate cancer, we have created a database of 3’UTR somatic mutations in 185 patients with mCRPC, discovering 14,497 single-nucleotide mutations throughout the 3’UTRome. In order to functionally assay these variants, we have developed a novel pair of massively parallel reporter assays (MPRA) able to determine the effect of thousands of patient somatic mutations on post-transcriptional gene expression. In this two-pronged approach, we are able to measure whether each of 6,892 mutations found in recurrently mutated 3’UTRs affect mRNA stability, steady-state transcript level, and translation efficiency. This deep functional assessment of thousands of 3’UTR mutations allows us to uncover patterns in mutation functionality, including their association with RNA motifs and sequence conservation. Investigation into how the resultant gene expression changes from 3’UTR mutations affect prostate cancer pathogenesis, such as cancer growth or response to treatment, is also underway. This work represents an unprecedented view of the extent to which disease-relevant 3’UTR mutations affect mRNA stability, translation efficiency, and cancer phenotypes, expanding the boundaries of functional cancer genomics and potentially uncovering novel therapeutic targets in previously unexplored regulatory regions.
2023-06-30 | GSE200302 | GEO